bioAffinity Technologies, Inc. (BIAF) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$3.33M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$3.62M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$2.29M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$2.52M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$3.33M | (m) | $1.51M | (m) | $89.97K* | -$3.20M* | (m) | $361.57K | $2.86M | (m) |
| 2026-03-31 | Reported | (m) | -$3.62M | (m) | $1.35M | (m) | $5.66K | -$3.23M | (m) | $349.71K | $3.24M | (m) |
| 2025-09-30 | Reported | (m) | -$2.29M | (m) | $1.45M | (m) | -$3.65K* | -$2.48M* | (m) | $330.59K | $2.21M | $3.18K |
| 2025-06-30 | Reported | (m) | -$2.52M | (m) | $1.27M | (m) | $13.43K* | -$2.65M* | (m) | $311.37K | $2.21M | $28.98K |
| 2025-03-31 | Reported | (m) | -$2.63M | (m) | $1.85M | (m) | $50.79K | -$1.64M | (m) | $367.39K | $2.45M | $8.70K |
| 2024-09-30 | Reported | (m) | -$1.97M | (m) | $2.35M | (m) | $9.41K* | -$1.71M* | (m) | $274.50K | $2.36M | $2.56K |
| 2024-06-30 | Reported | (m) | -$2.09M | (m) | $2.40M | (m) | $28.29K* | -$1.53M* | (m) | $402.43K | $2.47M | $5.42K |
| 2024-03-31 | Reported | (m) | -$1.95M | (m) | $2.41M | (m) | $41.39K | -$2.35M | (m) | $393.64K | $2.19M | $3.67K |
| 2023-09-30 | Reported | (m) | -$2.29M | (m) | $298.48K | (m) | $169.00* | -$1.53M* | (m) | $330.38K | $2.02M | $2.29K |
| 2023-06-30 | Reported | (m) | -$1.78M | (m) | $19.74K | (m) | $3.86K* | -$1.36M* | (m) | $335.13K | $1.40M | $4.59K |
| 2023-03-31 | Reported | (m) | -$1.56M | (m) | $921.00 | (m) | $32.31K | -$1.53M | (m) | $369.62K | $1.15M | $11.82K |
| 2022-09-30 | Reported | (m) | -$976.16K | (m) | $1.15K | (m) | (m) | -$1.76M* | (m) | $319.74K | $595.70K | $300.00 |
| 2022-06-30 | Reported | (m) | -$684.12K | (m) | $1.31K | (m) | (m) | -$376.14K* | (m) | $248.42K | $408.62K | $0.00* |
| 2022-03-31 | Reported | (m) | -$727.04K | (m) | (m) | (m) | (m) | -$633.97K | (m) | $279.85K | $394.69K | $2.16K |
| 2021-09-30 | Reported | (m) | -$526.29K | (m) | (m) | (m) | (m) | (m) | (m) | $330.77K | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$10.57M | (m) | $6.16M | (m) | $60.57K | -$9.33M | (m) | $1.38M | $9.91M | $44.04K |
| 2024-12-31 | Reported | (m) | -$8.95M | (m) | $9.36M | (m) | $79.08K | -$7.26M | (m) | $1.46M | $9.94M | $11.65K |
| 2023-12-31 | Reported | (m) | -$7.97M | (m) | $2.53M | (m) | $22.90K | -$6.04M | (m) | $1.47M | $6.79M | $20.99K |
| 2022-12-31 | Reported | (m) | -$4.01M | (m) | $4.80K | (m) | $219.99K | -$4.07M | (m) | $1.38M | $2.48M | $2.46K |
| 2021-12-31 | Reported | (m) | -$2.21M | (m) | (m) | (m) | (m) | -$2.05M | (m) | $1.01M | $1.07M | $1.95K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |